5 Questions for…Michael Silverberg
With December 1 marking World AIDS Day, this infectious disease expert looks at the state of HIV/AIDS research. And despite his Northern California location, admits he's a diehard Los Angeles Lakers fan.
Kaiser Permanente Research Featured at ID Week 2018
Kaiser Permanente Division of Research scientists recently presented research on influenza vaccines, colorectal screening outcomes in HIV-infected individuals, a genetic basis for fever after measles-containing vaccines, and more at ID Week, a leading conference on infectious diseases.
Q&A: Talking Flu Shots with Nicola Klein, Director of Kaiser Permanente’s Vaccine Study Center
Dr. Klein’s latest research raised some interesting questions about when influenza vaccinations are most effective, so we spoke with her to learn more and answer some common flu vaccine questions.
“Catch-up” HPV Vaccination Works for Females up to Age 20 Years at First Dose, Not Older Ages
Kaiser Permanente study confirms recommendations for catch-up HPV vaccination with 3 doses in females aged 15 to 20, but not when started at or after age 21.
Eight Weeks or Twelve? Kaiser Permanente Study Shows Shorter Hepatitis C Regimen Effective in Black Patients
A new study shows that a treatment regimen of 8 weeks for hepatitis C may be just as effective as 12 weeks in black patients. The study also showed that more people overall can take advantage of the shorter treatment durations, which has important implications for access given the medication’s high cost.
